Most recent articles by:

Editorial Team

- Advertisement -

FDA and CDC exploring unlikely relation between COVID-19 vaccine and stroke

The FDA and CDC have brought out new revelations that the revised COVID-19 injection from Pfizer Inc and its partner BioNTech could...

Disappointing sales prompt AstraZeneca to pull out leukemia drug Lumoxiti from U.S. market

In a letter shared with healthcare providers, AstraZeneca has announced that it will be pulling its leukemia antibody-drug conjugate Lumoxiti (moxetumomab pasudotox-tdfk)...

Sanofi’s Venture Capital units to receive over $750 million in investment to boost firm’s investment capabilities 

After a successful last year in which Sanofi Ventures made its second-highest number of deals, 10 rounds of backing that amount to...

Roche’s Xofluza approved by European Commission for children’s influenza treatment

The EC (European Commission) has approved Roche’s influenza treatment called Xofluxa, targeted toward children aged over a year. It can be used...

Delivering mRNA Into Extracellular Vesicles Decreases Wrinkles in Mice, Study Finds

Extracellular vesicles (EVs) have been found to be a viable alternative to lipid nanoparticles for the delivery of mRNA to mice's skin,...

Life Science Voice Top Five Newsletter January 2023

This week we see that abortion rights continue to be a hot topic in the country with the FDA allowing abortion pills...

Spiral Therapeutics completes $8.25M financing for phase 2 trial of hearing medication

Spiral Therapeutics has recently closed an $8.25 million financing round for the phase 2 research and development of SPT-2101, which is the...

Alphabet’s health subsidiary Verily cuts staff by 15% in a bid to strategize and reorganize

In an email shared with Verily employees recently, the company CEO Stephen Gillett announced that they will be laying off 15% of...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

Amgen’s KRAS drug gets early FDA approval for lung cancer with specific mutation

On Friday, the United States FDA (Food and Drug Administration) has authorized a medication of Amgen Biopharmaceutical in patients with NSCLC
- Advertisement -